| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/CR.2015.113 |
| P8608 | Fatcat ID | release_pbqw7abrufezzci7sbngxny464 |
| P932 | PMC publication ID | 4650419 |
| P698 | PubMed publication ID | 26391698 |
| P5875 | ResearchGate publication ID | 282130158 |
| P50 | author | Yuen Kwok-yung | Q8060280 |
| Stanley Perlman | Q57438616 | ||
| Jinghua Yan | Q88146803 | ||
| Jianxun Qi | Q90990686 | ||
| Guangwen Lu | Q91198453 | ||
| Yuhua Wan | Q125200832 | ||
| P2093 | author name string | Yan Li | |
| Ying Wu | |||
| George F Gao | |||
| Wenjun Liu | |||
| Jincun Zhao | |||
| Qihui Wang | |||
| Buchang Zhang | |||
| Peipei Liu | |||
| Xuancheng Lu | |||
| P2860 | cites work | Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC | Q24329089 |
| Structure of CD40 ligand in complex with the Fab fragment of a neutralizing humanized antibody | Q27634524 | ||
| The 1.85 A resolution crystal structures of tissue factor in complex with humanized Fab D3h44 and of free humanized Fab D3h44: revisiting the solvation of antigen combining sites | Q27635381 | ||
| Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4 | Q27678981 | ||
| Structure of the Fusion Core and Inhibition of Fusion by a Heptad Repeat Peptide Derived from the S Protein of Middle East Respiratory Syndrome Coronavirus | Q27680061 | ||
| Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor | Q27689029 | ||
| VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface | Q27765383 | ||
| A decade after SARS: strategies for controlling emerging coronaviruses | Q28817689 | ||
| Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia | Q29618053 | ||
| Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies | Q29619015 | ||
| Rapid generation of a mouse model for Middle East respiratory syndrome | Q30217177 | ||
| Is the discovery of the novel human betacoronavirus 2c EMC/2012 (HCoV-EMC) the beginning of another SARS-like pandemic? | Q30223960 | ||
| Interhuman transmissibility of Middle East respiratory syndrome coronavirus: estimation of pandemic risk. | Q30351904 | ||
| Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. | Q30362113 | ||
| Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development | Q30432706 | ||
| Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus | Q30482353 | ||
| Molecular signatures of hemagglutinin stem-directed heterosubtypic human neutralizing antibodies against influenza A viruses | Q33553746 | ||
| Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution | Q33627189 | ||
| Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques | Q33887877 | ||
| The spike protein of SARS-CoV--a target for vaccine and therapeutic development | Q34015988 | ||
| Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus | Q34193942 | ||
| Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. | Q34306978 | ||
| Identification of human single-chain antibodies with broad reactivity for noroviruses | Q34313167 | ||
| Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp | Q34426585 | ||
| Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests | Q34650448 | ||
| A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines | Q35063993 | ||
| Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein | Q35159147 | ||
| The analysis of VH and VL genes repertoires of Fab library built from peripheral B cells of human rabies virus vaccinated donors | Q35174377 | ||
| Spotlight on chronic lymphocytic leukemia: a Pharma Matters report | Q35220733 | ||
| Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection | Q35865538 | ||
| The molecular biology of coronaviruses | Q36550910 | ||
| Preventing severe respiratory syncytial virus disease: passive, active immunisation and new antivirals. | Q38182054 | ||
| Bat-to-human: spike features determining 'host jump' of coronaviruses SARS-CoV, MERS-CoV, and beyond | Q38553361 | ||
| Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. | Q41718118 | ||
| Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. | Q42152380 | ||
| Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies | Q42249511 | ||
| Evidence of person-to-person transmission within a family cluster of novel coronavirus infections, United Kingdom, February 2013. | Q42269949 | ||
| Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003. | Q42612038 | ||
| Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. | Q46274869 | ||
| MERS in South Korea and China: a potential outbreak threat? | Q51830239 | ||
| [Locoregional breast radiotherapy and concurrent treatment with trastuzumab]. | Q54383301 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| Middle East respiratory syndrome coronavirus | Q4902157 | ||
| P304 | page(s) | 1237-1249 | |
| P577 | publication date | 2015-09-22 | |
| P1433 | published in | Cell Research | Q1524018 |
| P1476 | title | A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein. | |
| P478 | volume | 25 |
| Q58710181 | A Human DPP4-Knockin Mouse's Susceptibility to Infection by Authentic and Pseudotyped MERS-CoV |
| Q93017024 | A Novel Bacterium-Like Particle Vaccine Displaying the MERS-CoV Receptor-Binding Domain Induces Specific Mucosal and Systemic Immune Responses in Mice |
| Q58693121 | A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV |
| Q84315469 | A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) |
| Q97519840 | A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS |
| Q95851276 | A human neutralizing antibody targets the receptor binding site of SARS-CoV-2 |
| Q30402347 | A novel neutralizing monoclonal antibody targeting the N-terminal domain of the MERS-CoV spike protein |
| Q40064548 | A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective. |
| Q30248209 | A review of treatment modalities for Middle East Respiratory Syndrome |
| Q61818480 | Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain |
| Q99418269 | Analysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition |
| Q95611861 | Analysis of the SARS-CoV-2 spike protein glycan shield: implications for immune recognition |
| Q84315455 | Antibodies and vaccines against Middle East respiratory syndrome coronavirus |
| Q102058982 | Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys |
| Q56558457 | Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infection |
| Q84315956 | Clinical outcomes among hospital patients with Middle East respiratory syndrome coronavirus (MERS-CoV) infection |
| Q34513643 | Coronaviruses - drug discovery and therapeutic options. |
| Q95602418 | Coronaviruses pandemics: Can neutralizing antibodies help? |
| Q30845557 | Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains |
| Q40061001 | Current treatment options and the role of peptides as potential therapeutic components for Middle East Respiratory Syndrome (MERS): A review |
| Q56971688 | Current understanding of middle east respiratory syndrome coronavirus infection in human and animal models |
| Q90130709 | Detection of MERS-CoV antigen on formalin-fixed paraffin-embedded nasal tissue of alpacas by immunohistochemistry using human monoclonal antibodies directed against different epitopes of the spike protein |
| Q36814211 | Development of Monoclonal Antibody and Diagnostic Test for Middle East Respiratory Syndrome Coronavirus Using Cell-Free Synthesized Nucleocapsid Antigen |
| Q90562656 | Development of a recombinant replication-deficient rabies virus-based bivalent-vaccine against MERS-CoV and rabies virus and its humoral immunogenicity in mice |
| Q100464664 | Development of an antibody-dependent cellular cytotoxicity reporter assay for measuring anti-Middle East Respiratory Syndrome antibody bioactivity |
| Q40252744 | Efficacy of antibody-based therapies against Middle East respiratory syndrome coronavirus (MERS-CoV) in common marmosets. |
| Q61818478 | From SARS to MERS, Thrusting Coronaviruses into the Spotlight |
| Q90723419 | Generation of a Nebulizable CDR-Modified MERS-CoV Neutralizing Human Antibody |
| Q40041480 | Identification of a Novel Inhibitor against Middle East Respiratory Syndrome Coronavirus |
| Q40083207 | Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. |
| Q51149122 | Importance of neutralizing monoclonal antibodies targeting multiple antigenic sites on MERS-CoV Spike to avoid neutralization escape. |
| Q96642693 | Landscape and Selection of Vaccine Epitopes in SARS-CoV-2 |
| Q108127425 | Landscape and selection of vaccine epitopes in SARS-CoV-2 |
| Q58595060 | MERS coronavirus outbreak: Implications for emerging viral infections |
| Q40317741 | MERS-CoV spike nanoparticles protect mice from MERS-CoV infection |
| Q30248743 | MERS-CoV spike protein: Targets for vaccines and therapeutics |
| Q30240139 | MERS-CoV spike protein: a key target for antivirals |
| Q39374922 | MERS-coronavirus: From discovery to intervention. |
| Q42628113 | Marburg virus-like particles by co-expression of glycoprotein and matrix protein in insect cells induces immune responses in mice |
| Q38840884 | Marburg virus-like particles produced in insect cells induce neutralizing antibodies in rhesus macaques. |
| Q84315478 | Middle East Respiratory Syndrome Coronavirus in Dromedaries in Ethiopia Is Antigenically Different From the Middle East Isolate EMC |
| Q40085786 | Middle East respiratory syndrome coronavirus: five years later. |
| Q91912232 | Molecular Characteristics, Functions, and Related Pathogenicity of MERS-CoV Proteins |
| Q99240136 | Nanomedicine strategies to target coronavirus |
| Q60925703 | Neutralizing Monoclonal Antibodies as Promising Therapeutics against Middle East Respiratory Syndrome Coronavirus Infection |
| Q30396959 | Novel chimeric virus-like particles vaccine displaying MERS-CoV receptor-binding domain induce specific humoral and cellular immune response in mice |
| Q37188934 | Passive Transfer of A Germline-like Neutralizing Human Monoclonal Antibody Protects Transgenic Mice Against Lethal Middle East Respiratory Syndrome Coronavirus Infection |
| Q39150633 | Passive immunotherapy for Middle East Respiratory Syndrome coronavirus infection with equine immunoglobulin or immunoglobulin fragments in a mouse model |
| Q90669974 | Production of a Monoclonal Antibody Targeting the M Protein of MERS-CoV for Detection of MERS-CoV Using a Synthetic Peptide Epitope Formulated with a CpG-DNA-Liposome Complex |
| Q56907500 | Prophylactic and therapeutic efficacy of mAb treatment against MERS-CoV in common marmosets |
| Q30249325 | SARS and MERS: recent insights into emerging coronaviruses |
| Q99240705 | SARS-CoV-2 vaccine research and development: conventional vaccines and biomimetic nanotechnology strategies |
| Q84315572 | Selection and Characterization of Monoclonal Antibodies Targeting Middle East Respiratory Syndrome Coronavirus through a Human Synthetic Fab Phage Display Library Panning |
| Q39677274 | Single-dose treatment with a humanized neutralizing antibody affords full protection of a human transgenic mouse model from lethal Middle East respiratory syndrome (MERS)-coronavirus infection |
| Q94571949 | Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies |
| Q90281592 | Structural Definition of a Neutralization-Sensitive Epitope on the MERS-CoV S1-NTD |
| Q89568621 | Structural Definition of a Unique Neutralization Epitope on the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein |
| Q90692545 | Structural Genomics of SARS-CoV-2 Indicates Evolutionary Conserved Functional Regions of Viral Proteins |
| Q91809315 | Structural definition of a neutralization epitope on the N-terminal domain of MERS-CoV spike glycoprotein |
| Q30241347 | T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV. |
| Q97676079 | Targeting SARS-CoV-2 RBD interface: a supervised computational data-driven approach to identify potential modulators |
| Q94545219 | The Current and Future State of Vaccines, Antivirals and Gene Therapies Against Emerging Coronaviruses |
| Q39144823 | The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection |
| Q63879931 | Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein |
| Q36555622 | Treatment strategies for Middle East respiratory syndrome coronavirus |
| Q64137589 | Ultrapotent Human Neutralizing Antibody Repertoires Against Middle East Respiratory Syndrome Coronavirus From a Recovered Patient |
| Q39034541 | Update on therapeutic options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV). |
| Q97592234 | Vaccines based on virus-like nano-particles for use against Middle East Respiratory Syndrome (MERS) coronavirus |
Search more.